PDS Biotechnology to Present at B. Riley Securities Virtual Oncology Conference
January 18 2022 - 8:00AM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® and Infectimune™ T-cell activating technologies
respectively, today announced that its management will present at
the B. Riley Securities Virtual Oncology Conference on January 28,
2022.
The presentation will provide an update on three
ongoing PDS0101 phase 2 clinical trials. In the Versatile-002 phase
2 clinical trial, PDS Biotech is collaborating with MERCK &
Co., to evaluate a combination of PDS0101 and KEYTRUDA®
(NCT04260126). Versatile-002 is studying the combination in
first-line treatment of recurrent or metastatic head and neck
cancer, and in second-line treatment of recurrent or metastatic
head and neck cancer in patients who have failed prior checkpoint
inhibitor therapy. In addition, the Company is conducting a phase 2
clinical study in both second- and third-line treatment of multiple
advanced HPV-associated cancers. This study is being led by the
National Cancer Institute (NCI). A third phase 2 clinical trial
(IMMUNOCERV) in first-line treatment of locally advanced cervical
cancer is being led by The University of Texas, MD Anderson Cancer
Center.
The presentation will also provide updates on
the progression of two other investigational pipeline
immune-oncology products. PDS0102 (Versamune® + TARP) addresses
prostate cancer, breast cancer and AML, and PDS0103 (Versamune® +
MUC1) addresses multiple cancers including breast, colon, lung, and
ovarian cancers.
The conference is taking place virtually on
January 28, 2022. Details for the presentation are as follows:
B. Riley Securities Virtual Oncology
ConferenceDate: Friday, January 28, 2022Time: 12:30 pm
ETInvestors can register for the conference HERE.
Following the conference, a webcast replay of
the presentation will be available on the Investor section of the
company’s website, PDS Biotechnology.
About PDS BiotechnologyPDS
Biotech is a clinical-stage immunotherapy company developing a
growing pipeline of cancer and infectious disease immunotherapies
based on the Company’s proprietary Versamune® and Infectimune™
T-cell activating technology platforms. Our Versamune®-based
products have demonstrated the potential to overcome the
limitations of current immunotherapy by inducing in vivo, large
quantities of high-quality, highly potent polyfunctional tumor
specific CD4+ helper and CD8+ killer T-cells. PDS Biotech has
developed multiple therapies, based on combinations of Versamune®
and disease-specific antigens, designed to train the immune system
to better recognize diseased cells and effectively attack and
destroy them. The Company’s pipeline products address various
cancers including HPV16-associated cancers (anal, cervical, head
and neck, penile, vaginal, vulvar) and breast, colon, lung,
prostate and ovarian cancers. Our Infectimune™ -based
vaccines have demonstrated the potential to induce not only robust
and durable neutralizing antibody responses, but also powerful
T-cell responses including long-lasting memory T-cell responses. To
learn more, please visit www.pdsbiotech.com or follow us on Twitter
at @PDSBiotech.
Investor Contact:
Rich CockrellCG CapitalPhone: +1 (404)
736-3838pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Aug 2024 to Sep 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Sep 2023 to Sep 2024